US 2017/0304300 A1 · HIF-2alpha INHIBITORS FOR TREATING IRON OVERLOAD DISORDERS

Abstract

The present disclosure relates to HIF-2α inhibitors and methods of making and using them for treating iron overload disorders. Certain compounds were potent in HIF-2α scintillation proximity assay, luciferase assay, and VEGF ELISA assay, and reduced liver iron accumulation and serum iron parameters in both prophylactic and treatment mouse models.

Claims24

Dependent claims

A method of preventing or treating an iron overload disorder comprising administering to a subject an effective amount of a small molecule HIF-2α inhibitor.

Dependencies are inferred from the claim text.

Facts

Application

15/517,528Filed 25 Sep 2015

Priority

10 Oct 2014

Published

26 Oct 2017

Term ends

Not estimatedThe source records don’t support an estimate.

Classification16 codes

A61K 31/4965
Having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines: non-condensed pyrazines
A61K 31/085
Ethers or acetals: having an ether linkage to aromatic ring nuclear carbon
A61K 31/09
Having an ether linkage to aromatic ring nuclear carbon: having two or more such linkages
A61K 31/10
Sulfur, selenium, or tellurium compounds, e.g. thiols: sulfides; Sulfoxides; Sulfones

Abstract

Claims24

Dependent claims

A method of preventing or treating an iron overload disorder comprising administering to a subject an effective amount of a small molecule HIF-2α inhibitor.

Dependencies are inferred from the claim text.

HIF-2alpha INHIBITORS FOR TREATING IRON OVERLOAD DISORDERS

Life of this patent

Abstract

Claims24

HIF-2alpha INHIBITORS FOR TREATING IRON OVERLOAD DISORDERS

Life of this patent

Abstract

Claims24